The research team, led by Kaisi Yang and corresponding authors Yingshi Zhang and Qingchun Zhao, working across Shenyang Pharmaceutical University, the General Hospital of Northern Theater Command, and Wannan Medical University Affiliated Tongling People’s Hospital, assembled a multi-layered case for ADAM8/17’s involvement in this cancer. Their investigation began with bioinformatic mining of publicly available gene expression datasets, which revealed that ADAM8 is highly and specifically overexpressed in intrahepatic cholangiocarcinoma compared with surrounding tissue and other tumor types. This pattern of selective elevation is exactly what drug developers look for in a target: a molecule that is abundant in the disease but dispensable elsewhere, minimizing the risk of collateral toxicity.

Correlation alone, however, has long been a trap in cancer genomics. Many genes are merely passengers that ride along with tumor progression without causing it. To address this, the team turned to Mendelian randomization, a statistical technique that uses naturally occurring genetic variants as instruments to test whether an exposure, in this case ADAM8/17 expression, plausibly causes a disease outcome rather than simply accompanying it. By combining two-sample Mendelian randomization analyses with a meta-analysis across independent datasets, the researchers found that genetically influenced ADAM8/17 activity and its downstream Notch signaling pathway were closely linked to the occurrence and development of intrahepatic cholangiocarcinoma. This causal framing substantially strengthens the argument that these proteases are active participants in tumor biology rather than bystanders.

ADAM8 and ADAM17 are membrane-anchored enzymes known as sheddases, meaning they cleave the extracellular portions of other membrane proteins and release them into the surrounding environment. Among their substrates are signaling molecules and receptors that fuel inflammation, angiogenesis, and cell proliferation. The Notch pathway, which the study implicates as a downstream mediator, is a highly conserved cell-to-cell communication system that governs cell fate decisions; when dysregulated, it can promote tumor growth, epithelial-mesenchymal transition, and resistance to therapy. The idea that blocking ADAM8/17 could simultaneously dampen Notch-driven malignancy gives the target additional mechanistic appeal.

Identifying a target is only half the battle; the harder task is finding a molecule that disables it. Through molecular docking simulations, the team screened for small compounds capable of binding the catalytic machinery of ADAM8/17 and landed on a candidate they designated NY-2. To confirm that the compound genuinely engages its target inside cells rather than merely fitting a computational model, the researchers employed a cellular thermal shift assay. This technique exploits a simple physical principle: proteins stabilized by a bound ligand resist heat-induced denaturation. The assay demonstrated that NY-2 shifts the thermal stability of ADAM8/17 in cells, providing direct biochemical evidence of target engagement, a step that many candidate drugs fail to clear.

With target engagement established, the team moved into functional testing using an impressive battery of models. Patient-derived organoids, miniature three-dimensional tumor cultures grown from actual patient tissue, retain much of the cellular diversity and drug responsiveness of the original tumors, making them a far more faithful testing ground than conventional cell lines. In these organoids, alongside standard MTT proliferation assays, Transwell migration experiments, apoptosis measurements, and cell cycle analyses, NY-2 consistently suppressed the hallmarks of cancer progression: cells stopped dividing, migration was curtailed, and programmed cell death increased. The compound also arrested cells at specific checkpoints in the cell cycle, further choking off tumor expansion.

The mechanistic payoff came from western blotting experiments that mapped exactly which signaling cascades NY-2 disrupts. The results showed that the compound acts through two converging arms. The first is the Notch1–HIF1α–VEGFA axis, a chain in which Notch1 signaling stabilizes the hypoxia-inducible factor HIF1α, which in turn drives vascular endothelial growth factor A production, fueling the blood vessel growth that tumors need to enlarge and spread. The second is the Integrinα5–TGFβ–Smad pathway, in which the adhesion molecule integrin alpha-5 feeds into transforming growth factor beta signaling and its intracellular Smad effectors, a circuit intimately tied to epithelial-mesenchymal transition, the process by which cancer cells acquire invasive and metastatic properties. By suppressing both routes simultaneously, NY-2 attacks the tumor’s growth supply line and its invasion machinery at once.

The clinical significance of these findings is sharpened by the study’s prognostic data, which showed that high ADAM8/17 expression is associated with poor outcomes in patients with intrahepatic cholangiocarcinoma. This dual role, as both a biomarker of aggressive disease and a pharmacologically actionable target, is rare and valuable. It suggests a future in which ADAM8/17 expression levels could help stratify patients most likely to benefit from a targeted inhibitor, moving treatment away from one-size-fits-all chemotherapy toward precision oncology for a cancer that desperately needs it.

The authors are careful to frame this as a foundation rather than a finished therapy. Their stated next steps include gene editing experiments to confirm the target’s necessity and orthotopic liver tumor models, in which tumors are implanted directly into the liver to recreate the organ environment more faithfully than subcutaneous models. Such studies will be essential before any compound derived from NY-2 can approach clinical trials, and the history of cancer drug development is littered with promising preclinical targets that failed to translate. Nevertheless, the breadth of evidence here, spanning population genetics, structural biology, thermal proteomics, and patient-derived models, gives the ADAM8/17 hypothesis unusual depth.

For patients with intrahepatic cholangiocarcinoma, whose five-year survival remains dismal and whose treatment options have barely expanded in decades, the identification of a druggable, causally implicated target with a validated small-molecule inhibitor is a genuinely encouraging signal. The work also exemplifies a modern drug discovery paradigm: computational biology to nominate a target, Mendelian randomization to establish causality, docking and thermal shift assays to validate engagement, and organoids to demonstrate efficacy. If subsequent in vivo studies confirm what this research suggests, ADAM8/17 inhibition could become one of the most closely watched strategies in biliary tract cancer therapeutics.

Subject of Research: The role of ADAM8/17 proteases and the Notch1/Integrinα5 pathway in the development and targeted treatment of intrahepatic cholangiocarcinoma

Article Title: Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway

Article References: Yang, K., Han, L., Song, X., Wang, C., Wang, Z., Zhu, Z., Xu, T., Mao, M., Xu, Z., Zhang, Y., & Zhao, Q. (2026). Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06616-4

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06616-4

Keywords: intrahepatic cholangiocarcinoma, ADAM8, ADAM17, NY-2 inhibitor, Notch1 signaling, Integrinα5, HIF1α, VEGFA, TGFβ-Smad pathway, Mendelian randomization, patient-derived organoids, targeted therapy

The answer, according to the study, is a resounding no — at least for the surgery itself. Using genetic mouse models in which HIF1α was specifically deleted from the intestinal epithelium, the researchers demonstrated that the absence of this factor did not diminish the dramatic metabolic improvements normally achieved after bariatric procedures. Mice lacking intestinal HIF1α still experienced the characteristic benefits of the surgery, including reduced body weight, improved glucose tolerance, and favorable changes in fat distribution. In other words, the celebrated metabolic rewiring triggered by bariatric surgery proceeds perfectly well without this oxygen-responsive transcription factor pulling the strings in the gut.

That finding alone would have been notable, but the study’s second act is where the story becomes genuinely intriguing. When the same HIF1α-deficient mice were challenged not with surgery but with a high-fat diet, the protective role of the protein suddenly came into sharp focus. Animals lacking intestinal HIF1α gained significantly more weight on the obesogenic diet than their genetically intact counterparts, and their livers told an equally sobering tale: hepatic steatosis, the abnormal accumulation of fat in liver tissue, developed more readily and more severely. The gut oxygen sensor, it turns out, is not a passive bystander in metabolic disease but an active defender against dietary stress.

This distinction between the two experimental contexts is scientifically meaningful rather than merely academic. Bariatric surgery operates largely through mechanisms independent of ordinary dietary physiology — rapid changes in bile acid signaling, gut hormone secretion, microbiome composition, and nutrient sensing that create a fundamentally altered metabolic environment. Diet-induced obesity, by contrast, unfolds gradually through the slow accumulation of caloric excess and the chronic, low-grade inflammatory and hypoxic stresses it imposes on tissues. HIF1α appears to be critical for withstanding the latter condition while being dispensable for the former, suggesting that the factor functions primarily as a buffer against the physiological consequences of nutrient overload rather than as a mediator of surgical metabolic reprogramming.

To appreciate why the intestine was the logical place to look, it helps to consider the unique biology of gut tissue. The intestinal epithelium sits at the interface between a nutrient-rich lumen and the oxygen-sensitive vasculature of the body, creating a physiological gradient that researchers describe as functional hypoxia. Even in healthy animals, the cells lining the gut experience oxygen levels far lower than most other tissues. HIF1α responds to this environment by activating dozens of target genes involved in barrier integrity, angiogenesis, glycolytic metabolism, and inflammatory regulation. Disrupting this system, the new data indicate, leaves the gut metabolically vulnerable in ways that ripple outward to the whole body, manifesting as increased adiposity and fatty liver disease.

The hepatic connection deserves particular attention. Non-alcoholic fatty liver disease affects roughly a quarter of the global population and represents one of the most serious downstream consequences of obesity, capable of progressing to inflammation, fibrosis, and cirrhosis. If intestinal HIF1α helps protect the liver from fat accumulation, then understanding the signaling pathway between the gut and the liver becomes a matter of substantial clinical relevance. The new findings point toward gut-derived signals — whether barrier-related, microbial, or endocrine — as modulators of hepatic lipid handling, reinforcing a growing body of evidence that liver health begins in the intestine.

Methodologically, the study relied on conditional knockout technology, a cornerstone of modern mouse genetics that allows researchers to remove a gene from a specific tissue while leaving it intact everywhere else. This precision matters enormously for HIF1α, a protein expressed throughout the body with roles ranging from red blood cell production to tumor biology. A whole-body deletion would be lethal or hopelessly confounded; an intestinal epithelium-specific deletion cleanly isolates the gut’s contribution. By comparing knockout and control animals across both surgical and dietary paradigms, the authors could disentangle two biological questions that had previously been tangled together: whether HIF1α transmits the benefits of bariatric surgery, and whether it defends against dietary obesity.

The clinical implications cut in several directions at once. For the millions of patients undergoing bariatric surgery each year, the findings offer reassurance of a negative kind: there is no evidence that natural variation in intestinal HIF1α function would blunt the surgery’s effectiveness. For the far larger population at risk of diet-induced obesity and fatty liver disease, however, the study highlights a potential therapeutic target. If pharmacological activation of intestinal HIF1α — through microbiome modulation, dietary interventions, or drug development — can mimic the protective effect observed in the mouse models, it could open a new avenue for preventing or treating metabolic disease without surgery.

That translational leap will require considerable additional work. Mouse models of obesity and bariatric surgery capture only part of human physiology, and HIF1α is a notoriously pleiotropic factor whose activation can carry risks as well as benefits, including contributions to certain cancers and inflammatory conditions. The researchers themselves are careful to frame the results as a foundation rather than a prescription. Still, the conceptual payoff is clear: the metabolic benefits of bariatric surgery and the body’s natural defenses against dietary obesity travel along partially separate molecular roads, and intestinal HIF1α stands as a guardian on one road but not the other.

As the global burden of obesity and its hepatic complications continues to climb, studies like this one refine the field’s understanding of where interventions can do the most good. Bariatric surgery will remain a powerful tool whose mechanisms are only gradually being mapped. Meanwhile, the humble oxygen sensor in the gut lining — a protein once studied mainly in the context of altitude adaptation and tumor hypoxia — has emerged as an unexpected protector of metabolic health, one whose full therapeutic potential is only beginning to be explored.

Subject of Research: The role of intestinal HIF1α in bariatric surgery outcomes, diet-induced obesity, and hepatic steatosis

Article Title: Intestinal HIF1α is dispensable for bariatric surgery-mediated metabolic benefits but protects against diet-induced obesity and hepatic steatosis

Article References: Cao, C., Liu, Y., Tan, X., Zhao, Y., Jaime, H., Chu, Y., He, M., Hua, R., Yao, Q., & Shao, Y. (2026). Intestinal HIF1α is dispensable for bariatric surgery-mediated metabolic benefits but protects against diet-induced obesity and hepatic steatosis. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02212-1

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02212-1

Keywords: HIF1α, bariatric surgery, diet-induced obesity, hepatic steatosis, intestinal epithelium, hypoxia signaling, metabolic disease, fatty liver, gut-liver axis, glucose tolerance, mouse models, International Journal of Obesity

The molecular logic of the HIF pathway is elegant. Under normal oxygen tensions, the alpha subunits of HIF, chiefly HIF1α and HIF2α, are continuously marked for destruction by prolyl hydroxylase domain enzymes, EGLN1 and EGLN2, which require molecular oxygen to hydroxylate specific proline residues. Once hydroxylated, the alpha subunits are captured by the von Hippel–Lindau ubiquitin ligase complex and rapidly degraded by the proteasome. When oxygen falls during ischaemia, hydroxylation stalls, HIFα accumulates within minutes, translocates to the nucleus, dimerizes with the constitutive ARNT subunit, and binds hypoxia response elements to switch on hundreds of hypoxia-responsive genes. Importantly, the review highlights that during reperfusion HIFs can remain stabilized even after oxygen returns, because ischaemic accumulation of Krebs cycle metabolites such as succinate inhibits prolyl hydroxylase activity, providing oxygen-independent stabilization that prolongs the transcriptional response precisely when injury is peaking.

Among the best-characterized HIF-dependent programmes is metabolic reprogramming. HIF1α induces pyruvate dehydrogenase kinase, which shunts pyruvate away from oxygen-hungry mitochondrial oxidation and towards glycolysis, a metabolic switch that allows cardiomyocytes to generate ATP with far less oxygen consumption. Experimental work shows that HIF1α also targets the mitochondrial permeability transition pore, a critical gatekeeper of reperfusion-induced cell death, thereby blunting the lethal calcium and reactive-oxygen-driven opening of this pore when blood flow resumes. More recently, glycolytic flux has been linked to epigenetic regulation through histone lactylation, in which lactate-derived modification of histones activates reparative gene programmes after infarction, suggesting that the metabolic shift driven by HIFs does more than produce energy; it rewires the gene-expression landscape of the injured heart toward survival and repair.

A second major axis of HIF-mediated cardioprotection involves extracellular adenosine signalling. Hypoxia-inducible factors upregulate ecto-5′-nucleotidase, or CD73, the enzyme that converts released AMP into adenosine, while simultaneously repressing adenosine kinase and equilibrative nucleoside transporters, thereby boosting extracellular adenosine concentrations at the very moment the heart needs them. Adenosine acting through A2A and A2B receptors on immune cells, endothelium and cardiomyocytes dampens inflammation, preserves microvascular barrier integrity and promotes tolerance to ischaemic stress. The review also details HIF2α-dependent induction of amphiregulin, a ligand that engages epidermal growth factor receptor pathways to reduce myocardial injury, and transcription-independent induction of ERBB1, illustrating that HIFs protect the heart through both classical gene transcription and rapid non-genomic mechanisms.

The two major HIF alpha isoforms are not interchangeable. HIF1α predominantly drives core hypoxic metabolism genes and is the dominant isoform in cardiomyocytes during acute ischaemia, whereas HIF2α has more restricted cell-type expression, prominent in endothelial cells, macrophages and stromal populations, and controls a partly distinct transcriptional portfolio involving growth factor signalling, angiogenesis, macrophage polarization and microRNA induction. Gene-targeting studies show that deleting HIF1α in cardiomyocytes abolishes preconditioning-induced protection, while HIF2α deletion in myeloid or endothelial compartments separately compromises repair and barrier function. The review emphasizes that this isoform specificity carries a cautionary message for drug development: blanket HIF activation may simultaneously trigger beneficial and detrimental programmes depending on which cell types and which isoforms are engaged, and precise tuning of prolyl hydroxylase inhibition may be key to maximizing benefit.

Perhaps the most compelling clinical framing of the HIF story comes from ischaemic preconditioning and its clinically translatable cousin, remote ischaemic conditioning. The landmark discovery that brief, repeated episodes of ischaemia dramatically protect the heart against subsequent prolonged ischaemia established that the myocardium possesses an endogenous survival programme waiting to be triggered. Multiple studies now demonstrate that HIF1 is required for this protection: mice with partial HIF1α deficiency lose preconditioning-induced cardioprotection entirely, and HIF1 is also indispensable for remote preconditioning, in which transient limb ischaemia protects the heart through circulating humoral and neural signals. Mechanistically, remote conditioning engages EGLN1 inhibition and metabolite rerouting, and downstream protection involves adenosine signalling, interleukin-10 induction and HIF-dependent metabolic adaptation, providing a molecular explanation for one of cardiology’s most studied protective interventions.

The review also weaves in a surprising temporal dimension: the circadian clock. Clinical observations spanning decades show that the incidence and severity of myocardial infarction vary by time of day, and recent work demonstrates that the clock component BMAL1 can partner with HIF2α to form a functional heterodimer that modulates circadian variation in myocardial injury susceptibility. The PER2 protein, stabilized through adenosine A2B receptor signalling, promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischaemia, while rhythmic oxygen fluctuations themselves reset circadian clocks through HIF1α. This reciprocal crosstalk between hypoxia sensing and circadian biology suggests that the timing of a heart attack, of cardiac surgery, or even of drug administration could meaningfully influence how much myocardium survives, opening the emerging field of circadian cardioprotective medicine.

What elevates this basic science into immediate translational territory is the fact that pharmacological HIF stabilizers already exist and are in clinical use. Oral inhibitors of HIF prolyl hydroxylases, including roxadustat, vadadustat, daprodustat, molidustat and enarodustat, have been approved or evaluated extensively for treating renal anaemia, because stabilizing HIF stimulates erythropoietin production and iron utilization. The review argues that this existing clinical infrastructure provides a ready-made pathway for evaluating HIF activation as a cardioprotective strategy in myocardial infarction, cardiac surgery and myocardial injury after non-cardiac surgery, the latter being a common and under-recognized cause of perioperative morbidity. Preclinical studies support this optimism: roxadustat markedly reduces myocardial ischaemia–reperfusion injury in mouse models, attenuates adverse remodelling after infarction, and protects diabetic myocardium by upregulating HIF1α-dependent antioxidant programmes.

The authors are careful to note the caveats. Chronic HIF activation carries risks, including pro-angiogenic effects relevant to cancer biology, erythrocytosis, and context-dependent inflammatory consequences, as illustrated by HIF2α gain-of-function syndromes and by the oncology use of the HIF2 antagonist belzutifan. Cardiovascular safety signals from the anaemia trials have been scrutinized, and the review stresses that acute, time-limited, precisely dosed HIF activation around the window of ischaemia and reperfusion is the cardioprotective concept, distinct from indefinite chronic therapy. Nevertheless, the convergence of mechanistic depth, isoform and cell-type knowledge, clinically validated small molecules and proven preconditioning paradigms positions HIF biology as one of the most plausible near-term routes to a therapy that has eluded cardiology for decades: reliably limiting the damage that both the blockage and the rescue inflict on the human heart.

The epidemiological backdrop gives this translational urgency its weight. Ischaemic heart disease remains the leading cause of death worldwide, and analyses from the Global Burden of Disease project document its continued expansion as populations age, while economic studies in the European Union attribute tens of billions of euros in annual costs to cardiovascular disease. Within surgical practice, elevated high-sensitivity troponin after non-cardiac surgery is associated with increased thirty-day mortality, making perioperative myocardial injury a target population in which a short-acting cardioprotective drug could be deployed prophylactically, before the ischaemic insult even occurs.

Historically, the field owes much to the foundational work of Gregg Semenza and colleagues, who in the early 1990s demonstrated cell-type-specific, hypoxia-inducible expression of the erythropoietin gene and subsequently purified hypoxia-inducible factor 1 as an oxygen-regulated heterodimer. The mechanistic resolution came in 2001, when parallel studies showed that oxygen sensing is achieved through prolyl hydroxylation of HIFα and its recognition by the von Hippel–Lindau ubiquitin ligase machinery, a discovery recognized with the 2019 Nobel Prize in Physiology or Medicine shared by Semenza and Peter Ratcliffe, alongside William Kaelin. That oxygen-sensing pathway is precisely what today’s oral prolyl hydroxylase inhibitors exploit.

The preconditioning literature adds an instructive dose of realism. Despite decades of robust animal data, attempts to translate conditioning paradigms into routine clinical practice have yielded mixed results, often attributed to species differences, comorbidities such as diabetes that blunt endogenous protective signalling, and concomitant medications including statins and opioids that engage overlapping pathways. The HIF framework offers a potential remedy: rather than relying on the body’s variable endogenous trigger, pharmacological stabilization of HIF could impose the protective programme directly, and preclinical work in diabetic models suggests that HIF1α-dependent antioxidant induction may restore protection where conditioning fails.

For clinicians watching this space, the near-term research agenda is discernible. The review points toward carefully designed trials of acute, time-limited HIF activation in the peri-infarct and perioperative windows, with attention to dosing, timing relative to reperfusion, and isoform-selective engagement. Whether the anaemia drugs can be repurposed at cardioprotective doses without erythrocytosis or vascular risks will determine if this long-sought therapy finally reaches the bedside.

Subject of Research: The role of hypoxia-inducible factors in myocardial ischaemia–reperfusion injury and cardioprotection

Article Title: The role of hypoxia-inducible factors in myocardial ischaemia–reperfusion injury and cardioprotection

Article References: Luo, C., Li, T., Tak, J., DeBerge, M., Tsai, K.-L., & Eltzschig, H. K. (2026). The role of hypoxia-inducible factors in myocardial ischaemia–reperfusion injury and cardioprotection. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-026-01339-y

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01339-y

Keywords: hypoxia-inducible factors, myocardial ischaemia-reperfusion injury, cardioprotection, HIF1α, HIF2α, prolyl hydroxylase inhibitors, ischemic preconditioning, adenosine signaling, glycolytic metabolism, circadian rhythm, roxadustat, heart attack